The American College of Cardiology (ACC) and the Duke Clinical Research Institute are recruiting hospitals enrolled in the ACC's NCDR CathPCI Registry to participate in an observational study—the TRANSLATE-ACS Study—to examine longitudinal outcomes, treatment patterns and healthcare costs for 15,000 patients with acute MI treated with PCI and antiplatelet medications.
The study will examine post-discharge care patterns and treatment adherence, and evaluate the safety, effectiveness and healthcare costs of antiplatelet therapy use among contemporary acute MI (AMI) patient populations treated with PCI.
"The TRANSLATE-ACS Study allows hospitals participating in the NCDR CathPCI Registry to extend data collection into the outpatient setting," according to the NCDR website.
Reimbursement is provided for each patient enrolled, and all patient follow up will be conducted by the Duke study team.
Reports provided quarterly on 30-day rehospitalization and medication usage rates can be used for in-hospital quality improvement efforts.
The number of patients each site will enroll varies based on AMI patient volume, but on average, each site can expect to enroll around 60 patients, according to the website. The study will enroll patients through June 2011.